ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC

Results from a phase II study of bevacizumab and erlotinib in people with advanced hereditary leiomyomatosis and papillary renal cell cancer (HLRCC) or sporadic papillary RCC were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. This study included 83 patients with papillary RCC. Half of the patients […]

read more

ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer

Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC) were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program over the weekend. The combination of pembrolizumab with axitinib continues to show improved efficacy in the treatment of advanced RCC […]

read more

ASCO 2020: Savolitinib is promising for the treatment of papillary renal cell carcinoma

In a study presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, the tyrosine kinase inhibitor (TKI) savolitinib was shown to be more effective and safer than sunitinib as a treatment for people with papillary renal cell carcinoma (RCC). Papillary renal cell carcinoma accounts for approximately 15% of all RCC, making […]

read more

Positive results from trial of cabozantinib plus nivolumab combination in untreated metastatic kidney cancer

Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating nivolumab (Opdivo) in combination with cabozantinib (Cabometyx) compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (RCC) were released today. These top-line results were positive for the combination treatment, which improved progression-free survival, overall survival and objective response rate compared to sunitinib. […]

read more

First-line immunotherapy combination treatments for metastatic kidney cancer

A meta-analysis of four major clinical trials of immunotherapy combinations for the first-line treatment of metastatic renal cell carcinoma (RCC) was published in the journal Clinical Genitourinary Cancer earlier this month. The analysis compared progression-free survival, overall survival and objective response rate from four major clinical trials: CheckMate 214 (nivolumab/ipilimumab vs sunitinib), Keynote-426 (pembrolizumab/axitinib vs […]

read more

Axitinib first-line treatment of papillary renal cell carcinoma

The majority of renal cell carcinomas (RCCs) are a subtype called clear cell RCC. Most drugs have been developed to treat this subtype of RCC, leaving people with other metastatic RCC subtypes with an unmet need for an effective treatment in the first-line. Papillary RCC (pRCC) represents 10-15% of renal cell carcinomas, and is not an insignificant subtype. […]

read more

Evaluation of brain metastases in patients with kidney cancer treated with avelumab plus axitinib

In this video interview from Practice Update, Dr Eric Jonasch from MD Anderson Cancer Center in the USA talks about some interesting data on brain metastases in patients who have received a combination therapy. Renal cell carcinoma (RCC) patients will develop brain metastases in about 10% to 20% of the time, and the treatment for […]

read more

Novel HIF-2a inhibitor for patients with advanced kidney cancer

In this interview with Practice Update, Dr Eric Jonasch from MD Anderson Cancer Center in the USA talks about the the novel hypoxia inducible factor (HIF)-2 alpha inhibitor for the treatment of previously treated advanced renal cell carcinoma (RCC). Dr Jonasch described how HIF-2 alpha works and then went on to talk about the results […]

read more

First-line treatment of papillary renal cell carcinoma with sunitinib

Papillary renal cell carcinoma (PRCC) is a rare subtype of renal cell carcinoma (RCC), accounting for 10%-15% of all cases of RCC. There are two types of papillary RCC; type 1 and type 2. Currently, there is an unmet need for an effective first-line treatment for metastatic PRCC. A recent phase 2 study, published in […]

read more

Prognosis of type 1 and type 2 papillary renal cell carcinoma

In a recent analysis of a large database, researchers compared baseline clinical/pathological characteristics and survival outcomes of localised type 1 papillary renal cell carcinoma (pRCC) and type 2 pRCC patients. This study, the largest study of localised pRCC published to date, showed that type 2 pRCC patients were more likely to be diagnosed with higher […]

read more
Showing 11 to 20 of 71 results
  TOP